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ABSTRACT 
Objective: The objective of the study was to develop and validate a new rapid and more sensitive Reverse Phase High-Performance Liquid 
Chromatography (RP-HPLC) method for the simultaneous estimation of azithromycin, fluconazole and ornidazole in bulk and pharmaceutical 
dosage forms. 
Methods: Separation was achieved with a cap cell pack C18 column (4.6 x 250 mm, 5μ) with an isocratic mobile phase containing a mixture of 
acetonitrile and phosphate buffer pH 4.8 [adjusted with ortho-phosphoric acid] (50:50 % v/v) at the flow rate of 1 ml/min and detection was 
monitored at 210 nm. 
Results: The retention time (Rt) of azithromycin, fluconazole and ornidazole were found to be 4.82±0.01, 5.25±0.01 and 6.33±0.01 min 
respectively. The precision was found with<1.5% of %RSD. The calibration curve was linear over the concentration ranging from 500-1000 µg/ml 
for azithromycin, 75-150 µg/ml for fluconazole and 375-750 µg/ml for ornidazole with the correlation coefficient (r2
Conclusion: A simple isocratic liquid chromatographic method was developed and validated for simultaneous estimation of azithromycin, fluconazole 
and ornidazole in their formulations. Due to its simplicity, rapidness and specificity, it can be applied for routine quality control analysis of these drugs. 
) of 0.999. The percentage 
recovery was found to be within the specified range i.e., 98-102 % for three drugs. Limit of detection (LOD) was found to be 5.810, 1.790 and 4.924 
µg/ml, whereas Limit of quantification limits (LOQ) was found to be 9.834, 2.667 and 7.980 µg/ml, respectively. 
Keywords: Azithromycin, Fluconazole, Ornidazole, Method development, RP-HPLC 




Azithromycin is an antibiotic useful for the treatment of a number of 
bacterial infections, including middle ear infections, strep throat, 
pneumonia, traveler’s diarrhea and certain other infections. It is also 
used for sexually transmitted infections such as chlamydia and 
gonorrhea. It is chemically derived from erythromycin; it acts on 
bacterial protein synthesis by binding to the 50S ribosomal subunit 
of the bacterial 70S ribosome. Thereby, inhibits peptidyl transferase 
activity and interferes with amino acid translocation during the 
process of translation.  
Fluconazole is an anti-fungal medication which is being used in the 
number of fungal infections. It is primarily used in the treatment of 
candidiasis, blastomycosis, coccidiomycosis, cryptococcosis, histo-
plasmosis, dermatophytosis and pityriasis versicolor. It is a drug of 
choice in prevention of candidiasis during organ transplantation.  
Ornidazole is a drug that cures some protozoan infections. It has 
been investigated for use in Crohn’s disease after bowel resection. It 
is used for the treatment of stomach, intestinal, urinary tract and 
genital infections. Formation of redox intermediate (an intracellular 
metabolite) is believed to be the key component responsible for 
killing microorganisms. 
Combination of azithromycin, fluconazole and ornidazole were co-
administered to treat a variety of skin infections such as eczema, 
fungal skin infections including ringworm etc. Combination therapy 
commonly administered in the trade name of AF-kit (azithromycin-
1000 mg; ornidazole-750 mg and fluconazole-150 mg) (fig. 1). As 
these drugs are frequently co-administered in various infections, an 
effective, simple and specific analytical method is required for 
simultaneous estimation, thereby it will be helpful in the 
quantification of drugs in the formulation as well as in the biological 
matrices. An extensive literature survey suggests that development 
of various analytical techniques such as ultraviolet (UV)-visible 
spectroscopy [1-6], HPLC [6-24], HPTLC [25-28] and LCMS [29-32] 
for quantification of these drugs either in individual or combination 
with other drugs. Recently, Krishna et al., [21] reported an RP-HPLC 
method with the help of sodium dihydrogen ortho-phosphate (pH-
5.2): acetonitrile in the ratio of 70:30 (%v/v) as mobile phase. 
Another study by Arunya et al., [24] reported a stability-indicating 
RP-HPLC method for simultaneous estimation of these drugs with 
the help of procaine hydrochloride as an internal standard (IS). In 
the present study, we attempted to achieve a more precise and 
simple HPLC method by varying the chromatographic conditions. In 
our study, the separation and quantification were achieved with the 
help of phosphate buffer (pH-4.8): acetonitrile in 50:50 % v/v ratio 
as a mobile phase without using any IS. Moreover, the rapid elution 
with shorter runtime was observed at 4.82±0.01, 5.25±0.01 and 
6.33±0.01 min for azithromycin, fluconazole and ornidazole, 
respectively. In addition, the proposed method was validated as per 
ICH guidelines in terms of various parameters, and the results were 
found to be within acceptance criteria. In these studies, the method 
was found to be simple, rapid and more precise. 
 
 
Fig. 1: Chemical structures of azithromycin, fluconazole and 
ornidazole 
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MATERIALS AND METHODS 
Instrumentation 
Lab India UV-3000+
Chemicals and reagents 
double beam UV-Visible spectrophotometer was 
used to carry out absorption studies and the data were recorded by 
UV-Win software. Standard cuvettes of 10 mm path length were 
used for analysis. Cyber lab LC-100 HPLC system is accomplished 
with UV-detector, quantitative HPLC was performed on an isocratic 
mode using cap cell pack C18 (4.6 x 250 mm, 5µ) column with 20 μL 
injections of the sample loop. The output signal was monitored and 
integrated using Cyber lab LC-100 software. Lifecare ultra-sonic 
cleaner was used to sonicate the standard and sample solutions.  
Standard drugs of azithromycin, fluconazole and ornidazole were 
obtained as gift samples from Cipla Laboratory, Malapur and 
Aurobindo Pharmaceuticals, Hyderabad. Market formulation (AF-kit, 
Madras Pharmaceuticals, Chennai) was procured from the local 
market. HPLC grade acetonitrile and methanol were obtained from 
Merck Life Sciences, Mumbai, India. Analytical grade solvents and 
other chemicals were acquired from SD Fine Chemicals, Mumbai, 
India. Water was obtained from millipore with milli Q system, 
filtered through 0.45 µ nylon membrane for the HPLC experiments.  
Preparation of phosphate buffer 
Phosphate buffer was prepared by dissolving 13.6 g of potassium 
dihydrogen ortho-phosphate in 1000 ml of water (HPLC grade) and 
pH was adjusted to 4.8 with ortho-phosphoric acid and solution was 
filtered through 0.45 µ millipore nylon filter. 
Preparation of the mobile phase 
Acetonitrile: phosphate buffer (pH-4.8) in the ratio of 50:50 % v/v 
was prepared and it was filtered through 0.45 µ millipore nylon 
filter. The solution was degassed with ultrasonic cleaner for 15 min. 
The resultant solution was used as the mobile phase. 
Chromatographic conditions 
The method was developed by using a cap cell pack C18 column (4.6 
x 250 mm, 5μ) with an isocratic mobile phase which consists a 
mixture of acetonitrile and potassium dihydrogen ortho-phosphate 
buffer (pH-4.8 adjusted with ortho-phosphoric acid) in 50:50 % v/v 
ratio. The mobile phase was filtered through 0.45 µ millipore nylon 
filter under vacuum filtration. Flow rate of the mobile phase was 
adjusted to 1 ml/min. The eluted compounds were detected at the 
wavelength of 210 nm. The sample injection volume was 20 μl. 
Preparation of a standard mixture of azithromycin, fluconazole 
and ornidazole 
Transfer 100 mg of azithromycin, 15 mg of fluconazole and 75 mg of 
ornidazole into a 100 ml of volumetric flask and add 70 ml of diluent. 
Then it was sonicated for 15 min and the volume made up to 100 ml 
with diluent. The resulted solution (20 µl) was injected into the HPLC 
system by employing optimized chromatographic conditions. 
Preparation of sample mixture of azithromycin, fluconazole and 
ornidazole 
Twenty tablets of each of azithromycin, fluconazole and ornidazole 
(AF-Kit) were weighed and the average weight of each tablet was 
determined individually. The tablets were crushed into a fine 
powder, accurately weighed tablet powder equivalent to 100 mg 
(0.1121 g) of azithromycin, 15 mg (0.239 g) of fluconazole and 75 
mg (0.169 g) of ornidazole and transferred into a clean 100 ml 
volumetric flask. Add 70 ml of diluents, and then sonicated for 15 
min to dissolve, made up to the volume with diluents. The resulted 
solution was filtered through 0.45µ membrane filter and then above 
resulted solution 20 µl was injected into the HPLC system. 
Selection of detection wavelength  
The standard stock solution of azithromycin, fluconazole and 
ornidazole in the concentration of 10 μg/ml was prepared and each 
solution was scanned in UV range (200-400 nm) in 10 mm path 
length against the solvent blank. The overlain spectrum of three 
drugs was recorded against solvent blank. 
Method validation 
Method validation was performed using standard and sample 
solutions of analytes as per ICH guidelines for proposed method [33-
35]. The following validation parameters performed such as 
specificity, linearity, precision, accuracy, robustness, LOD and LOQ etc. 
RESULTS 
The purpose of the present study was to develop a rapid and 
sensitive RP-HPLC method for the simultaneous estimation of 
azithromycin, fluconazole and ornidazole in their dosage form using 
cap cell pack C18 analytical column with UV detection. 
Selection of detection wavelength  
The study of the absorption spectrum for three drugs revealed that 
well-defined ʎmax
 
. The iso-absorptive point was obtained at 210 nm 
for three drugs at the given concentration. Obtained wavelength 
maxima and iso-absorptive point for the three drugs were used for 
the simultaneous estimation by using RP-HPLC method. The 
overlain spectrum of azithromycin, fluconazole and ornidazole was 
shown in fig. 2. 
 




Optimization of chromatographic conditions for isocratic RP-HPLC  
detection, parameters such as mobile phase composition, pH (4.8-6.3) 
and flow rate (1 ml/min±0.2) were varied for system suitability 
studies. The variation in the mobile phase led to considerable changes 
in the chromatographic parameters like asymmetric factor, capacity 
factor and retention time (Rt). Varying in pH showed that optimized 
conditions were reached at pH 4.8, producing well resolved and sharp 
peaks for three drugs. Henceforth, in the present method, the 
acetonitrile and phosphate buffer (50:50 % v/v) (pH-4.8) was used as 
a mobile phase with 1.0 ml/min flow rate as optimal conditions. The 
detection of peaks achieved at 210 nm for the three analyte drugs. For 
quantitative determination of azithromycin, fluconazole and 
ornidazole in formulations, initially mixed standard solutions in 
appropriate concentrations were injected into the column and Rt’s of 
azithromycin, fluconazole and ornidazole was found to be 4.82±0.01, 
5.25±0.01 and 6.33±0.01 min, respectively (fig. 3). 
Method validation  
Method validation was performed as per ICH guidelines for 
simultaneous determination of the azithromycin, fluconazole and 
ornidazole. The results of parameters such as specificity, linearity, 
precision, accuracy, robustness, detection limit, quantification limit 
were described in the following sections. 
Specificity 
No interference of additives peak was found in the chromatogram 
for three drugs in tablet formulation, which indicates the proposed 
method is specific. Blank determination also performed where no 
appearance or interference of peaks observed. 
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Linearity 
Standard solutions at six different concentration levels ranging from 
500-1000 µg/ml for azithromycin, 75-150 µg/ml for fluconazole and 
375-750 µg/ml for ornidazole were prepared and analyzed in order 
to demonstrate the linearity relationships. For linearity study, the 
standard solutions were prepared as per label claim amount in the 
tablets. The regression curve was obtained by plotting the peak area 
v/s concentration of each analyte (fig. 4-6). It was obtained by least-
squares method [15]. The correlation coefficient (r2
 
) values were 
found to 0.999 for all the drugs. Detailed Linearity data were 
summarized in table 1. 
 
Fig. 3: Standard chromatogram of azithromycin, fluconazole and ornidazole in acetonitrile and phosphate buffer pH-4.8 (50:50%v/v) 
 
 
Fig. 4: Calibration curve of azithromycin (1000-500 µg/ml) 
 
 
Fig. 5: Calibration curve of fluconazole (75-150 µg/ml) 
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Fig. 6: Calibration curve of ornidazole (375-750 µg/ml) 
 
Table 1: Linearity data of azithromycin, fluconazole, ornidazole 
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Fig. 7: Chromatogram of 50% standard addition (level-1) 
 
 
Fig. 8: Chromatogram of 100% standard addition (level-2) 
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Accuracy 
Standard addition experiments were employed for accuracy studies 
in which the percent (%) recovery was determined. Accuracy of the 
method was evaluated in triplicate at three concentration levels, i.e. 
50 %, 100 % and 150 % of target concentration and the percentages 
of recoveries were calculated. Resulted chromatograms at these 
levels were shown in fig. 7-9. Percentage recoveries of three drugs 
found in between 98.3-101.2 %, which indicates the results obtained 
were within the potency range (table 2-4). 
 
 
Fig. 9: Chromatogram of 150% standard addition (level-3) 
 
Table 2: Accuracy data of azithromycin (n = 3) 





















































 n = number of determinations, SD = Standard deviation, % RSD = % Relative standard deviation 
 
Table 3: Accuracy data of fluconazole (n= 3) 














































n = number of determinations, SD = Standard deviation, % RSD = % Relative standard deviation 
 
Table 4: Accuracy data of ornidazole (n = 3) 
















































 n = number of determinations, SD = Standard deviation, % RSD = % Relative standard deviation 
 
Precision 
Precision of the method was determined by injecting the standard 
and sample solutions of azithromycin, fluconazole and ornidazole 
separately for six times and measured % RSD with the help of peak 
area for all six injections. System precision was established by 
injecting six replicate injections of standard solutions into the 
chromatographic system by maintaining the optimized conditions. 
Method precision was established by injecting six replicate 
injections of sample solution into the chromatographic system by 
Malothu et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 8, 26-34 
31 
maintaining the optimized conditions. In both cases, the % RSD 
found to be <2%, which indicate the proposed method was more 
precise. The precision data were summarized in table 5 and 6. 
Robustness 
Robustness experiments were carried by altering chromatographic 
conditions such as flow rate and detection wavelength to 
demonstrate any deliberate changes in the proposed method. The 
changes were made in the chromatographic conditions, viz. change 
in flow rate by ±0.2 ml/min and change in the wavelength ±5 °C. The 
% RSD was found <2% for three drugs even slight change of flow 
rate as well as detection wavelength (table 7, 8 and 9). As there were 
no significant variations in elution time for all the three drugs, 
indicate the method was robust. 
 
Table 5: System precision data of azithromycin, fluconazole and ornidazole (n=3) 
S. No. Rt Peak area Height of peak 
Azithromycin Fluconazole Ornidazole Azithromycin Fluconazole Ornidazole Azithromycin Fluconazole Ornidazole 
1 4.81 5.25 6.33 438629 383393 560485 49692 43189 70042 
2 4.82 5.26 6.34 438732 383871 564479 49343 43163 70861 
3 4.81 5.26 6.32 429781 383878 566369 49461 43258 70932 
4 4.82 5.25 6.32 429658 386958 568349 49461 43281 70865 
5 4.81 5.24 6.34 429268 386215 566332 49586 43856 70832 
6 4.82 5.25 6.33 429658 386115 565891 49856 43328 70156 
mean±SD 4.83 5.26 6.33 432621±3268.5 385071±232.5 565317±1639.1 - - - 
 % RSD - - - 0.75 0.06 0.28 - - - 
n = number of determinations, SD = Standard deviation, % RSD = % Relative standard deviation 
 
Table 6: Method precision data of azithromycin, fluconazole and ornidazole (n=3) 
S. No. Azithromycin Fluconazole Ornidazole 
Rt Peak area Rt Peak area Rt Peak area 
Injection-1 4.81 438654 5.25 395978 6.33 576369 
Injection-2 4.81 438962 5.26 396710 6.33 579209 
Injection-3 4.82 446756 5.25 396748 6.33 576432 
Injection-4 4.82 448756 5.25 397864 6.34 578659 
Injection-5 4.81 448851 5.25 396324 6.33 578956 
Injection-6 4.81 446231 5.26 395224 6.32 576354 
mean±SD 4.82 444701.0±3031.6 5.24 396474.6±89.41 6.33 577713.1±932 
% RSD - 0.68 - 0.02 - 0.16 
n = number of determinations, SD = Standard deviation, % RSD = % Relative standard deviation 
 
Table 7: Robustness data of azithromycin 
Factor Level Mean±SD of area %RSD 
Flow rate 
(ml/min) 
0.8  427494.5±1579.11 0.36 
1  438808±217.78 0.04 
1.2 428998.5±494.26 0.11 
Wavelength 
(nm) 
205 554261±84.852 0.01 
210 435941.7±3800.6 0.87 
215 544333±13231.3 0.16 
n = number of determinations, SD = Standard deviation, % RSD = % Relative standard deviation 
 
Table 8: Robustness data of fluconazole 
Factor Level Mean±SD of area %RSD 
Flow rate 
(ml/min) 
0.8 385962.5±744.58 0.19 
1  396168±268.70 0.06 
1.2  386261.5±451.84 0.11 
Wavelength(nm) 205  484532.5±1274.91 0.26 
210  383603±56.56 0.01 
215  485995±500.63 0.10 
n = number of determinations, SD = Standard deviation, % RSD = % Relative standard deviation 
 
Table 9: Robustness data of ornidazole 
Factor Level Mean±SD of area %RSD 
Flow rate 
(ml/min) 
0.8  567256±2265.5 0.39 
1  577789±2007.82 0.34 
1.2  568794.5±207.18 0.03 
Wavelength 
(nm) 
205 625212.5±566.39 0.09 
210 563655±268.7 0.04 
215 625656.5±371.23 0.05 
 n = number of determinations, SD = Standard deviation, % RSD = % Relative standard deviation 
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Limits of detection and quantification (LOD and LOQ) 
The sensitivity of the method was measured by calculating the LOD 
and LOQ. LOD and LOQ were assessed as per ICH guidelines, i.e., at 
signals to noise ratio of 3:1 and 10:1 respectively by injecting a 
series of dilute solutions with known concentrations (fig. 10 and 11). 
The linear regression equation was plotted for concentration v/s 
area of the peak. The standard deviation of y-intercepts and slope 
were considered for determination of sensitivity ranges for LOD and 
LOQ (table 10 and 11). 
  
 
Fig. 10: Chromatogram of LOD studies 
 
Table 10: LOD data of azithromycin, fluconazole and ornidazole (n = 3) 
S. No. Drug Peak area LOD (µg/ml) 
1 Azithromycin 2157 5.810 
2 Fluconazole 9950 1.790 
3 Ornidazole 57739.2 4.924 
n = number of determinations. 
 
 
Fig. 11: Chromatogram of LOQ studies 
 
Table 11: LOQ Data of azithromycin, fluconazole and ornidazole (n = 3) 
S. No. Drug Peak area LOQ (µg/ml) 
1 Azithromycin 3878 9.834 
2 Fluconazole 14887 2.667 
3 Ornidazole 96232.1 7.980 
 n = number of determinations. 
 
DISCUSSION 
The present study describes the development and validation of a RP-
HPLC method for simultaneous estimation of azithromycin, 
fluconazole and ornidazole in bulk drug and in their tablet dosage 
form. The separation was achieved on cell pack C18 column (4.6 × 
250 mm, 5µ) with UV detection. The method involves with 
acetonitrile and phosphate buffer pH-4.8 (50:50 % v/v) as mobile 
phase. The flow rate was monitored at 1.0 ml/min with an injection 
volume 20 μl. The separation was achieved by UV-detection 
wavelength at 210 nm. The peaks were eluted at 4.82±0.01, 
5.25±0.01 and 6.33±0.01 min for azithromycin, fluconazole and 
ornidazole, respectively which was found with a short time of 
elution and well resolved to that of the reported method [22].  
The decrease in buffer content (aqueous content) as well as 
adjusting pH at 4.8 of the mobile phase system resulted in rapid 
elution of fluconazole (RT-5.25 min). The system suitability 
parameters such as theoretical plates and tailing factor were found 
to be 8310, 1.0 (azithromycin), 8288, 1.8 (fluconazole) and 11846, 
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1.5 (ornidazole). Linearity was found over the concentration range 
of 500-1000 µg/ml for azithromycin, 75-150 µg/ml for fluconazole 
and 375-750 µg/ml for ornidazole with a correlation coefficient (r2
CONCLUSION 
) 
of 0.999 for three drugs. The method found to be more accurate with 
% recoveries of 100-102 %, 99-100 % and 98-102 % for 
azithromycin, fluconazole and ornidazole, respectively. LOD values 
were 5.810 µg/ml (azithromycin), 1.790 µg/ml (fluconazole) and 
4.924 µg/ml (ornidazole). LOQ values were 9.834 µg/ml 
(azithromycin), 2.667 µg/ml (fluconazole) and 7.980 µg/ml 
(ornidazole). The present liquid chromatographic method was found 
that it is as more appropriate for simultaneous estimation of such 
multi-component (three-drug combinations) pharmaceutical dosage 
forms. 
A simple, accurate and precise RP-HPLC method has been developed 
for the estimation of azithromycin, fluconazole and ornidazole in tablet 
dosage form using UV-detector. A RP-cell pack C18 column (4.6 × 250 
mm, 5 µ) with a mobile phase consisting of acetonitrile and phosphate 
buffer (pH-4.8) (50:50 % v/v) at 1 ml/min flow rate was used and the 
effluents were monitored at 210 nm. The results obtained by the 
proposed method were found as highly resolved, rapid with shorter 
runtime over previous reported methods. The peaks were eluted at 
4.82±0.01, 5.25±0.01 and 6.33±0.01 min, respectively. The percentage 
of recoveries were found as 100-102 %, 99-100 % and 98-102% with 
accepted limits of % RSD (<2%) for three drugs, respectively. The 
present RP-HPLC method developed was well suitable for routine 
analysis of these drugs in their pharmaceutical formulation and it can 
be also applicable to biological samples. 
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